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Abstract 
Rationale: Histamine and dopamine contribute to the maintenance of wakefulness. 
Objective: Exploratory analysis of the effects of 10 and 50 mg of MK-0249, a novel 
histamine subtype-3 receptor inverse agonist, and 200 mg of modafinil, a presumed 
dopaminergic compound, on EEG power spectra during sleep deprivation and subsequent 
recovery sleep. Methods: 25 healthy men were recruited to a double-blind placebo-
controlled cross-over design. EEG power spectra, an electrophysiological marker of 
changes in sleepiness and vigilance, were obtained at the beginning of wake maintenance 
tests at 2 hourly intervals throughout a night and day of sleep deprivation, which is an 
established model of excessive sleepiness. Results: After placebo, sleep deprivation was 
associated with enhancements in delta, theta and reductions in alpha and beta activity. 
Following dosing at 02:00, MK-0249 and modafinil reduced delta and theta activity and 
enhanced alpha and beta activity, compared to placebo. During recovery sleep initiated at 
21:00 h, latency to sleep onset, and number of awakenings were not different from placebo 
for any of the active treatments. Wake after sleep onset and stage 1 % was increased and 
total sleep time, SWS % and REM% were reduced after both doses of MK-0249. Compared 
to placebo, MK-0249 and the 50 mg dose in particular, reduced activity in some delta and 
theta/alpha frequencies and enhanced beta activity during NREM sleep and REM sleep. 
After modafinil, no changes were observed for power spectra during sleep.  Conclusion: 
both MK-0249 and modafinil exert effects on the EEG which are consistent with wake 
promotion.  
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Introduction 
Wake and sleep propensity vary with time awake (sleep homeostasis) and time of day 
(circadian phase) and excessive sleepiness is present in conditions such as narcolepsy, 
untreated sleep apnea, shiftwork sleep disorder and hypersomnia (Leibowitz et al. 2006). 
Changes in sleep-wake propensity can be assessed objectively by testing the ability to 
initiate sleep in the multiple sleep latency test (MSLT) or the ability to maintain 
wakefulness in the maintenance of wakefulness test (MWT) (Littner et al. 2005). The 
spectral composition of the EEG is an electrophysiological correlate of changes in 
sleepiness and vigilance. It has been shown repeatedly that during sleep deprivation EEG 
power in theta and delta activity increases and alpha activity decreases (Aeschbach et al. 
1999;Akerstedt and Gillberg 1990;Cajochen et al. 1995). Analysis of the contribution of 
circadian phase and time awake during forced desynchrony have confirmed that these 
changes in the EEG are related to an interaction of a circadian alerting signal, in part 
reflected in EEG alpha activity, and a signal associated with the increase in sleep pressure 
during sustained wakefulness, reflected in an increase in delta and theta activity  (Cajochen, 
et al. 2002). During the day, wakefulness and vigilance is maintained through activating 
neurotransmitters such as noradrenaline, dopamine, orexin and histamine, originating from 
brainstem and hypothalamic nuclei (Saper et al. 2005). These neurotransmitter systems are 
in part under circadian control and as we enter the biological night the strengths of these 
activating signals dissipates and sleepiness ensues (Dijk and Czeisler 1995). The extended 
wakefulness associated with sleep deprivation activates sleep homeostatic processes and 
associated changes in a variety of sleep regulatory substances, such as adenosine and TNF 
alpha, which also contribute to increased sleepiness and changes in the EEG (Krueger et al. 
2008).   
These neurochemical mechanisms underlying variations in sleep-wake propensity offer 
potential targets for sleepiness reducing/wake promoting interventions. Classical sleepiness 
reducing/wake promoting interventions target the noradrenergic/and dopaminergic systems 
(amphetamine) and adenosine (caffeine). A more recently developed wakefulness 
promoting compound (modafinil) appears to target the dopaminergic system, although there 
remains some debate about the precise mechanisms of action and it may currently not be 
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possible to define modafinil by a single mechanism of action (Bonnet, et al. 2005;Qu et al. 
2008).  
The histaminergic system is well placed to modify sleepiness because it has wide spread 
projections to many brain areas, is under circadian control, and is at least part of the 
pathway by which orexin exerts its effects on sleep propensity (Haas et al. 2008). 
Histaminergic neurons in the tuberomammillary nuclei are silent during NREM and REM 
sleep and are active during wakefulness, particularly during attentive wakefulness but not 
during drowsiness (Takahashi et al. 2006). It therefore appears that activity of histaminergic 
neurons is an important contributor to maintenance of vigilance.  
Histaminergic tone is inhibited through constitutive activity of the H3 receptor, i.e. a pre-
synaptic autoreceptor (Haas et al. 2008;Leurs et al. 2005). Inverse agonists of this receptor 
will increase synthesis and release of histamine and can thereby potentially reduce 
sleepiness in humans. Preclinical studies have shown that antagonists of the H3 receptor 
can induce wakefulness and that these effects are, unlike the wake promoting effects of 
modafinil, abolished in H3 receptor KO mice, demonstrating the very different mechanisms 
of actions of the two compounds (Parmentier et al. 2007). In one clinical study, reduction of 
sleepiness in narcoleptic patients was observed after administration of  a H3- inverse 
agonists (Lin et al. 2008). In that study, however, no objective EEG data during either 
wakefulness or sleep were reported and it is currently not known how H3 antagonists and 
H3 inverse agonists affect the EEG during wakefulness and sleep.  
We previously reported that the novel H3 inverse agonist MK-0249, similar to modafinil, 
exerts significant wake promoting effects as assessed by the latency to sleep onset during 
MWTs in a sleep deprivation paradigm (Iannone, et al. 2010). In that report we did not 
present data on the quantitative analysis of the EEG during the sleep deprivation or during 
the recovery sleep. To further characterize the effects of MK-0249 and modafinil on sleep-
wake propensity we analysed EEG power spectra during the MWT (Chapotot et al. 2003) 
and subsequent recovery sleep, as well as sleep structure. Assessment of sleep following 
administration of a wake promoting compound is important in order to assess any residual 
alerting effects that may interfere with sleep when it is desired. A primary question of 
interest in the present analysis was whether these two compounds, which both have wake 
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promoting effects but very different mechanism of actions, have similar effects on the 
spectral composition of the EEG during wakefulness and sleep, as well as sleep structure. 
 
Methods: 
This report is based on an exploratory analysis of a randomized, double blind, double 
dummy, placebo and modafinil controlled, 4 period crossover study (Merck and Co., Inc. 
Protocol MK-0249 007-01). The aim of the study was to assess the acute wake promoting 
effects of MK 0249 using a sleep deprivation model in healthy male volunteers. The 
primary outcome variable of this study was sleep latency on the MWT, and these data have 
been reported elsewhere (Iannone et al. 2010). Here we report data on the effects of MK-
0249 and modafinil on the spectral composition of the EEG during the MWT, sleep 
structure during recovery sleep as well as effects on the spectral compostion of NREM and 
REM sleep. Details of the protocol can be found in (Iannone et al. 2010). 
The study was performed at the Clinical Research Centre of the University of Surrey 
between October 2006 and February 2007. The protocol was approved by the Medicines 
and Healthcare products Regulatory Authority and the Ravenscourt Ethics Committee.  
 
Subjects 
25 male volunteers were recruited, aged between 18 and 45yrs. Participants had a BMI of 
between 19 and 31kg/m2 and were free from any pre-existing pathological conditions 
including neurological, psychiatric, cardiovascular, respiratory, endocrine, vascular, 
haematological, gastrointestinal, hepatic, renal and genitourinary and any evidence or 
history of cancer. Participants gave written informed consent prior to any study procedures 
being conducted. A physician judged each participant to be healthy based on their ECG, 
medical history, physical examination, haematology, blood chemistry and urinalysis tests. 
Participants discontinued any medications for 14 days prior to day 1 and throughout the 
study. Those that were unable to do this were excluded from the study, with the exception 
of treatment for minor ailments. Participants showed no evidence of epileptic EEG activity 
during screening. During an acclimatisation stay in the unit, participants who fell asleep 
within 15 minutes of a 20 minute Maintenance of Wakefulness Test (MWT) after 
approximately 25hrs of continuous wakefulness were eligible for inclusion.  Participants 
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smoking more than 5 cigarettes per day were not eligible and smoking was not allowed 
while participants were in the laboratory. Participants agreed not to consume any 
caffeinated beverages for 24hrs prior to each admission into the Surrey CRC and for the 
duration of their stay. Participants had not travelled through any time zones for 14 days 
prior to their acclimatisation stay and throughout the study. Participants were not shift 
workers, did not suffer from any sleep disorders, were deemed to have normal sleep habits 
and typically commenced habitual sleep between 20:00 and 00:00h. 
 
Protocol 
During each of the 4 treatment periods of the study, participants had an 8hr baseline sleep 
opportunity from 23:00 to 07:00 and were then kept awake until 21:00 on day 2 resulting in 
38hrs of continuous wakefulness, at which time they commenced a 12hr recovery sleep 
opportunity (Figure 1).  
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MWTs were performed in a sound attenuated, light controlled individual bedroom at 0800 
on day 1 and at 2 hourly intervals from 0000 until 2000 on day 2, as illustrated in Figure 1. 
Participants also completed a series of psychometric tests as part of the protocol, the result 
of which are presented in (Iannone et al. 2010). During times when participants were not 
completing tests they were allowed to move around in the unit and carry out various 
activities such as watching TV, playing games and reading.  These activities were strictly 
controlled and consistent throughout the study periods. To ensure that subjects were awake, 
they were under continuous surveillance and not allowed to sit in comfortable chairs. 
 
Drug administration occurred at 0200 on day 2 and consisted of a single dose of either 
200mg of modafinil, 10 or 50 mg of MK-0249 or placebo. 10 and 50 mg of MK-0249 are 
expected to result in 88 and 93% receptor occupancy respectively (Iannone et al. 2010). 
Administration was carried out in a double-blind, double-dummy fashion and there was a 
washout period of at least 7 days between each of the 4 treatment periods. 
 
EEG recordings during MWTs and Sleep Episodes 
All PSG recordings for both sleep and waking EEG were electronically captured through 
the Siesta system (Compumedics, Abbotsford, Victoria, Australia). The montage for this 
study was C3-A2, C4-A1, O1-A2 and O2-A1, in addition to two EMG and two EOG 
channels for both sleep and wake recordings. All EEG signals were low-pass filtered at 
70Hz and high-pass filtered with a time constant of 0.33sec which corresponds to a cut off 
frequency of 0.53Hz. Sampling rate was 256Hz and the data were stored at 128Hz for EEG, 
EOG and EMG signals. Data collected on the Siesta system was transmitted via Bluetooth 
and recorded directly to a computer file server and later downloaded into EDF files. 
 
Spectral analysis 
All wake and sleep EEG recordings were visually inspected and 2 second (MWT) or 4 
second epochs (Sleep EEG) containing artefacts were annotated manually using Vitascore 
software (Temec, The Netherlands). Epochs annotated as artefacts were excluded from the 
analysis of the power spectra. Spectral analysis was conducted using a fast Fourier 
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Transform after the data were weighted with a squared cosine window, implemented in the 
Vitascore software.  Power spectra were computed per 2 seconds, resulting in a 0.5 Hz 
resolution for the MWT EEGs. For the sleep EEG spectra were computed per 4 seconds, 
resulting in a 0.25 Hz resolution.  
 
Scoring and processing of MWT EEG data 
The first 2 minutes of EEG which was free from any significant movement artefact within 
the first 5 minutes of each MWT were selected by the first author for analysis. Any further 
artefacts were then manually removed from these 2min periods of data. At least 20sec of 
data had to be available after artefact removal for data to be included in the final dataset of 
power density values. It was considered that any less than this may not have given an 
accurate representation of the EEG being sampled. Analysis of these two minute periods 
was carried out regardless of vigilance state, and for waking EEG only. In this report EEG 
data during the MWT will be presented independent of vigilance state.  
 
Scoring and processing of Sleep EEG data  
A 12hr recovery sleep episode commenced at 21:00h on day 2, after 38hrs of continuous 
wakefulness and 19hrs after drug administration (Figure 1). Sleep stages and power spectra 
data were analysed to assess the effects of both 10 and 50mg of MK-0249 and modafinil on 
recovery sleep, compared to placebo. Sleep records were scored by the first author on a 30 
second epoch basis according to the established criteria of Rechtschaffen and Kales 
(Rechtschaffen and Kales 1968). From this standard sleep parameters were calculated. 
They include latencies to sleep onset, defined as the first occurrence of stage 2, 3, 4 or 
REM sleep, the duration of stages 1,2,3,4, SWS and REM sleep, number and duration of 
sleep cycles, total sleep time (TST), sleep efficiency, i.e. TST/Time between lights-off and 
lights-on, the number of sleep stage changes, the number of awakenings (NAW) and wake 
after sleep onset (WASO) EEG data were then subjected to FFT power density spectral 
analysis, as described above and sleep stage specific power spectra were computed. Data 
for the entire 12hr recovery sleep episode was analysed in addition to the first 8hrs of the 
sleep episode in order to assess the effects of an extended recovery sleep opportunity and a 
typical 8hr sleep opportunity, both of which may represent ‘real-life’ scenarios. 
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Statistics 
 
A statistical analysis plan for these exploratory analyses was established prior to review of 
the data. All statistical analyses were carried out using SAS®, version 9.1.  
Analysis of MWT data 
In order to assess the effect of sleep deprivation, spectral data of each MWT in each subject 
were expressed relative to the baseline of this subject, which was the average of MWTs 1,2, 
and 3. These analyses were conducted with a resolution of 1 Hz. Ratios were log 
transformed and difference from baseline were assessed by a students t-test.  
 To assess the effects of the various treatments, values in each MWT and each frequency 
bin were expressed relative to the corresponding placebo value. A paired student’s t-test 
was used to assess significant differences from placebo at each frequency from 1 to 25Hz 
on log transformed data. The level of significance used throughout was 0.05 and no 
correction for multiplicity was made. This obviously increases the likelihood of false 
positives. We nevertheless feel that this approach is justified because a) this is an 
exploratory analyses, b) it will allow for a direct comparison to previous studies,  e.g. 
(Tinguely, Finelli et al. 2006) c) spectral values of adjacent frequency bins are highly 
correlated which makes selecting the appropriate correction for multiplicity problematic d) 
there is prior knowledge on the effects of sleep deprivation and modafinil on EEG power 
spectra on the MWT. 
Visual inspection of the data shows that the significant effects are clustered in specific 
frequency ranges in accordance with prior studies and are unlikely to reflect statistical 
artefact.  
 
Analysis of sleep EEG data. 
Sleep Stages 
Comparisons between conditions were made using SAS PROX MIXED with treatment and 
period as fixed factors and subject as a random factor, followed by the LS MEANS 
statement to compute the p-value of the contrast between conditions. The significance level 
used throughout was 0.05. 
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EEG power spectra during sleep 
Power density spectra were created and a paired Student’s t-test was used to assess 
significant differences from placebo at each frequency from 1 to 25Hz on log transformed 
data for the sleep stage specific spectral data. The difference between treatment groups and 
placebo for PSG measures were also assessed using linear mixed effects model.   
 
One of the 25 enrolled subjects dropped out after Period 1 and was subsequently replaced 
and not included in the EEG analysis. Thus 24 subjects were included in the analyses but 
please note that for some of the comparisons the number of subjects may be less than 24 
due to missing data. 
 
Results: 
Effects of Sleep Deprivation on EEG power spectra at the beginning of MWT   
To document the effects of sleep deprivation on the EEG during the MWT, the EEG 
spectral data following dosing with placebo were expressed relative to the data collected 
pre-dosing, i.e. at MWT1 at 08:00, MWT2 at 0:00 and MWT 3 02:00 (See Figure 1). Sleep 
deprivation led to a substantial increase in low frequency activity, from 1 to 7Hz, in both 
central and occipital derivations (Figure 2).  The changes were observed from 2 to 6 hours 
post-placebo dose, 8 to 12 and 14 to 18 hours post-dose. Evidence for a progressive 
increase in EEG power density was only observed in the 1 and 2 Hz bins, in which values 
at the later sampling times of 8 to 12 and 14 to 18 hours post-dose, were greater compared 
to those of 2 to 6 hours post-dose. Sleep deprivation also led to a reduction in alpha activity 
(10-11 and 10-12 Hz for the central and occipital derivation respectively). A significant 
increase in EEG activity with the sigma band was only observed at 14 Hz in the central 
derivation. Beta activity was reduced between 18 and 22 Hz in the central derivation and 
17-25 Hz in the occipital derivation. 
 
Effects of MK-0249 and Modafinil on EEG Power Spectra  at the Beginning of MWT 
The effects of the two doses of MK-0249 and Modafinil on the EEG were analyzed by 
comparing EEG power spectra in these three active conditions to the placebo condition for 
both the central (Figure 3) and occipital derivation (Figure 4). Comparison of the EEG 
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power spectra pre-dosing, (i.e. baseline values) revealed very few differences across 
conditions.  By contrast, post-dosing many differences emerged when the EEG power 
spectra at the beginning of the MWT were analyzed for the interval 2 to 6, 8 to 12 and 14 to 
18 hours post-dose (Figure 3 and Figure 4).  In the 2-6 h post dose interval, modafinil and 
both doses of MK-0249 reduced low frequency activity up to approximately 6-7 Hz. During 
this interval all three active treatments enhanced alpha and beta activity in both the central 
and occipital derivation. During the 8-12 and 14 to 18 hours post-dose intervals, differences 
with placebo became in general smaller.  Whereas in the modafinil condition the reduction 
of delta and theta activity persisted in the 8-12 and 14-18 hours post-dose interval, the 
spectral values in this frequency range after both doses of MK-0249 were no longer 
significantly different from placebo during these time periods. By contrast, the effects on 
alpha and beta activity in particular, appeared to persist throughout the 18 hours post-dose 
interval for all three active treatments, most clearly so for the highest dose of MK-0249.  
 
Effects of MK-0249 and Modafinil on Sleep Initiation, Sleep Maintenance and Sleep 
Structure Following Sleep Deprivation. 
No significant differences between placebo and modafinil or placebo and either dose of 
MK-0249 were observed for measures of sleep initiation, i.e. latency to sleep onset and 
latency to persistent sleep (Table 1). The latency to SWS and REM sleep was also not 
significantly affected by the active treatments. The number and duration of sleep cycles was 
neither affected by modafinil nor any of the two doses of MK-0249.  
Both 10 and 50mg of MK-0249 reduced total sleep time while modafinil did not. Less SWS 
and more stage 1 sleep were present after administration of 10mg of MK-0249. In addition 
to these changes, 50mg of MK-0249 also significantly reduced the percentage of stage 2 
sleep, compared to placebo. REM sleep was also reduced by administration of both doses 
of MK-0249. Modafinil did not affect any sleep stage, either analyzed for the entire 12 h 
sleep episode or first 8 hours of the recovery sleep episode.  
 
The number of sleep stage changes was lower after administration of 50mg of MK-0249. 
No significant differences in the number of awakenings were present after administration of 
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modafinil or either dose of MK-0249. However wake after sleep onset was increased by 
both doses of MK-0249.  
 
These differences between placebo and active treatments for the entire recovery sleep 
episode were largely replicated when only the first 8hrs of sleep were analysed with the 
exceptions that the increase in stage 2 sleep after administration of 50mg of MK-0249 and 
the reduction in REM sleep after administration of 10mg of MK-0249 did not reach 
statistical significance when the analysis was limited to the first 8 hours.  
 
Effect of Modafinil and MK-0249 on EEG power spectra in NREM and REM sleep during 
recovery sleep 
Effects of the treatments on the spectral composition of the EEG were investigated by 
analyzing power spectra per third of the 12-h sleep episode, for the central and occipital 
derivation and separately for NREM (Figure 5) and REM sleep (Figure 6).  
 
The analysis revealed that modafinil had no consistent effects on EEG power spectra during 
either NREM or REM sleep in any of the intervals and derivations analyzed. By contrast, 
both doses of MK-0249 reduced very low frequency (0.25-2.0 Hz) activity and increased 
high spindle and beta activity in NREM sleep in both the central and occipital derivation. 
The latter effects were most pronounced for the highest dose.  The enhancement of beta 
activity and the reduction of low delta during NREM sleep persisted throughout the 12 hour 
sleep episode primarily after the higher dose of MK-0249 and in both central and occipital 
derivation. Furthermore, the higher dose of MK-0249 reduced theta activity at 7 and 8Hz 
during NREM sleep but this effect was observed only in the central derivation.  
 
Dose-dependent effects of MK-0249 on EEG power spectra during REM sleep were 
observed. The highest dose of MK-0249 led to an enhancement of beta activity during 
REM sleep which was primarily observed in the central deprivation. The highest dose 
reduced very low frequency and theta activity which was primarily observed in the 
occipital derivation. The analysis per third of the night did not suggest that these effects on 
EEG power spectra dissipated in the course of the sleep episode.  
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Discussion 
The effects of sleep deprivation on EEG power spectra during the MWT as observed in the 
present study are in accordance with previous reports showing enhancement of low 
frequency EEG activity and reduction in alpha activity during the MWT (Chapotot et al. 
2003) or during the Karolinska Drowsiness Test (KDT) with eyes open (Akerstedt and 
Gillberg 1990) (Aeschbach et al. 1999). These effects persisted throughout the entire sleep 
deprivation period. Whereas in some previous reports sleep deprivation was associated with 
an increase in beta activity (Dumont et al. 1999), a decrease in beta EEG activity was 
observed in the present study. In the present study we also observed an increase in sigma 
activity. These minor discrepancies may be related to the use of the MWT vs. the KDT. 
Overall, the robust effects of sleep deprivation on the EEG power spectra at the beginning 
of the MWT, which can be summarized as an increase in delta and theta activity and a 
reduction in alpha activity, demonstrate the sensitivity of this method for detecting changes 
in vigilance under placebo conditions.  
The effects of both MK-0249 and modafinil on EEG power spectra at the beginning of the 
MWT can be summarized as ‘countering the effects of sleep deprivation’. Thus the “drug 
induced-wakefulness" or "pharmacological sleep deprivation” was characterized by effects 
which were to a large extent a mirror image of the effects of sleep deprivation under 
placebo.   In the first 6 hours post-dose both compounds reduced delta and theta activity 
and enhanced alpha activity. In addition, the compounds enhanced beta activity. Modafinil 
induced reduction of delta and theta activity was previously reported in a helicopter 
simulator study (Caldwell, Jr. et al. 2000), although in that study no enhancement of alpha 
or beta activity was reported. In a previous sleep-deprivation-MWT study (Chapotot et al. 
2003), modafinil was reported to enhance alpha activity but not beta activity. Modafinil 
also reduced theta activity in that study, although significantly so only at a few time points. 
In that study, the effects of the stimulant d-amphetamine were also assessed and it was 
found that d-amphetamine reduced theta activity throughout the sleep deprivation, but did 
not significantly enhance alpha activity. Based on these previous studies with modafinil and 
d-amphetamine, as well as the effects of the stimulant caffeine (Landolt et al. 2004), and 
the effects of sleep deprivation under placebo it can be concluded that a reduction of delta 
and theta and enhancement of alpha activity are part of an alerting EEG signature. The 
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effects of MK-0249 on the EEG to a large extent encompass this alerting EEG signature. 
Not much evidence for a dose effect was found and this may indicate that the lower dose of 
MK-0249 has already near maximal effects. In the first six hours post-dose, the effects on 
EEG power spectra were very similar for modafinil and MK02409, despite their different 
mechanism of action.  
The observed differences between modafinil and MK-0249 with respect to the time course 
of the effects on EEG powers spectra appeared frequency specific. The enhancement of 
beta activity, and to some extent alpha activity, persisted throughout the 18 h post-dose 
period for all active treatments. The reduction in delta and theta activity remained 
significant for approximately 14 h post dose period after modafinil administration but only 
for the first 4 hours or so after MK-0249. These frequency specific differences may relate 
to the different mechanism of actions or different pharmacokinetics of the two drugs.  
 
During recovery sleep, initiated 19 hours following dosing with MK-0249, EEG power 
spectra in both NREM and REM sleep were altered relative to baseline. The effects differed 
between REM and NREM sleep and between the doses; for REM sleep the effects appeared 
to depend on EEG derivation as well. Sleep stage and EEG derivation specific effects have 
previously been reported after other pharmacological interventions.  The effects of MK-
0249 on EEG power spectra during NREM sleep and REM sleep are very different from 
the effects of compounds such as benzodiazepine and non-benzodiazepine agonists of the 
synaptic and extra synaptic GABA receptor (Borbely et al. 1985;Brunner et al. 1991;Dijk, 
et al. 2009;Trachsel et al. 1990), 5HT2 antagonists (Dijk et al. 1989;Landolt et al. 1999) and 
alcohol (Dijk et al. 1992).  The effects of MK-0249 and of the higher dose in particular on 
EEG power spectra during NREM sleep, probably reflect residual alerting effects because 
the number of awakenings and wake after sleep onset were also increased relative to 
placebo. These effects were, however, relatively mild, because sleep onset and the number 
of awakenings were not affected, although sleep efficiency, SWS% an REM% were 
suppressed. Thus our data suggest that modulation of the histaminergic system by MK-
0249 appears to affect cortical activation and vigilance state. 
EEG power spectra during NREM sleep and REM sleep were not affected by modafinil, 
even though analysis of the MWT EEG data suggested some maintained efficacy up to 18 
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hours post dose, i.e. one hour prior to the start of recovery sleep. This may indicate that the 
effects of modafinil on sleep EEG power spectra differ from its effects on the EEG during 
wakefulness. In other words, the effects of modafinil on the EEG are vigilance state 
specific: modafinil affects the EEG during wakefulness but not during sleep. Alternatively, 
these observations may simply imply that 19 hours post-dose the wake promoting effects of 
modafinil, with a half-life of 10-12 hours, have dissipated too much to still affect the sleep 
EEG and the effects of MK-0249, with a half-life of approximately 14 hours, may still be 
present. The lack of an effect of modafinil compared to placebo, on the EEG during 
recovery sleep following sleep deprivation contrast the effects of, for example, caffeine 
administration during sleep deprivation. Caffeine, in contrast to modafinil, does not just 
inhibit the expression of a sleep debt but rather reduce the build up of sleep pressure during 
wakefulness (Landolt, et al. 2004). The lack of an effect of modafinil on EEG power 
spectra during NREM sleep is in accordance with the absence of an effect on sleep 
structure and sleep maintenance measures. These finding are in accordance with previous 
studies from which it was concluded that modafinil does not disrupt sleep if administration 
takes place 10 hours or more before the start of sleep (Bonnet et al. 2005).  Please note that 
after neither MK-0249 nor modafinil the rebound of SWS or TST following sleep 
deprivation exceed the placebo values.    
Overall the data show that the H3-inverse agonist MK 0249 has robust effects on the EEG 
during sleep deprivation, as well as effects on the EEG during sleep. The latter effects 
appeared dose dependent and may also depend on the mechanisms of action of the two 
compounds. Despite the very different mechanism of action of modafinil and MK-0249, the 
effects of the two compounds on the EEG during sleep deprivation were rather similar. 
These data support the notion that H3-inverse agonists, similar to modafinil, have robust 
wake promoting effects. 
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Figure 1: Protocol used to assess the wake-promoting effects of MK-0249 and modafinil.  
Yellow represents periods of wakefulness and black represents scheduled sleep periods. 
Arrows indicate MWT time points and time of drug administration which occurred at 0200, 
just after the third MWT. 2 minutes of data from the beginning of each MWT was used to 
assess the effects of MK-0249 and modafinil, in comparison to placebo, on the EEG 
throughout the period of sleep deprivation. 
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Figure 2: Effects of sleep deprivation on EEG power spectra during MWTs in the placebo 
condition 
Power spectra for 2 to 6 (MWTs 4 to 6 combined; n=24; black circles), 8 to 12 (MWTs 7 to 
9 combined; n=24; red circles) and 14 to 18hrs (MWTs 10 to 12 combined; n=24; blue 
circles) post-dose, expressed as a percentage of baseline (spectra for MWTs 1 to 3, prior to 
drug administration), for central (left) and occipital (right) derivations, in the placebo 
condition. Black, blue and red circles along the x-axis indicate significant differences 
between baseline and 2 to 6hrs, 8 to 12hrs and 14 to 18hrs post-dose respectively. 
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Figure 3: Comparison of the effects of modafinil and MK-0249 with placebo on EEG 
power spectra during MWTs for 4hr time bins in the central derivation  
Central derivation EEG power density spectra of wake and sleep EEG combined for MWTs 
binned each 4hrs for modafinil (red triangles, n = 22 in top two panels and 23 in bottom 
two panels), MK-0249 10mg (blue circles, n = 24) and MK-0249 50mg (green squares, n = 
24) expressed as a percentage of placebo for each MWT time point. Red triangles, blue 
circles and green squares on the x-axis indicate significant differences between placebo and 
modafinil, MK-0249 10mg and MK-0249 50mg respectively, p<0.05. 
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Figure 4: Comparison of the effects of modafinil and MK-0249 with placebo on EEG 
power spectra during MWTs for 4hr time bins in the occipital derivation 
Occipital derivation EEG power density spectra of wake and sleep EEG combined for 
MWTs binned each 4hrs for modafinil (red triangles, n = 23) and MK-0249 10mg (blue 
circles, n = 24) and 50mg (green squares, n = 24) expressed as a percentage of placebo for 
each MWT time point. Red triangles, blue circles and green squares on the x-axis indicate 
significant differences between placebo and modafinil, MK-0249 10mg and MK-0249 
50mg respectively, p<0.05. 
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Figure 5: Effects of modafinil and MK-0249 on EEG NREM power density spectra per 
third of the night 
Power density spectra expressed as a percentage of placebo for the first (left), second 
(middle) and third (right) thirds of the recovery night for central (top row) and occipital 
(bottom row) derivations after administration of modafinil (red lines and filled triangles, n 
= 21), MK-0249 10mg (blue lines and open circles, n = 22) and MK-0249 50mg (green 
lines and filled squares, n = 22 in A, B and C and 21 in D, E and F). Blue circles and green 
squares along the x-axis indicate a significant difference between placebo MK-0249 10mg 
and MK-0249 50mg respectively, P<0.05. 
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Figure 6: Effects of modafinil and MK-0249 on EEG REM power density spectra per 
third of the night 
Power density spectra expressed as a percentage of placebo for the first (left), second 
middle) and third (right) thirds of the recovery night for central (top row) and 
occipital (bottom row) derivations after administration of modafinil (red lines and 
filled triangles, n = 21 in A to E and 20 in F), MK-0249 10mg (blue lines and open 
circles, n = 22 in A to E and 21 in F) and MK-0249 50mg (green lines and filled 
squares, n = 22 in B and C, 21 in A, E and F). Red triangles, blue circles and green 
squares along the x-axis indicate a significant difference between placebo and 
modafinil, MK-0249 10mg and MK-0249 50mg respectively, P<0.05. 
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Table 1: PSG assessment of sleep after administration of modafinil and MK-0249 
compared to placebo for the entire 12 hour recovery sleep episode 
PSG variables (mean ±SE) after administration of placebo (n=22), modafinil (n=23), 
MK-0249 10mg (n=24) and MK-0249 50mg (n=24). Effect of treatment was assessed 
with repeated measures ANOVA and p values are listed. Abbreviations used are as 
follows: sleep onset latency (SOL), slow wave sleep (SWS), rapid eye movement 
(REM), latency to persistent sleep (LPS), total sleep time (TST), number of 
awakenings (NAW) wake after sleep onset (WASO). * indicates a significant 
difference from placebo; * = P<0.05, ** = P<0.01 and *** = P<0.001. 
 
Treatment Placebo Modafinil MK0249 10mg MK0249 50mg
SOL (min) 5.7 ± 0.87 13.3 ± 2.7 14.1 ± 2.7 8.4 ± 1.6
SWS latency (min) 23.4 ± 5.9 24.5 ± 3.2 32.1 ± 5.6 41.3 ± 11.6
REM latency (min) 65.9 ± 4.5 65.7 ± 4.7 63.5 ± 6.1 80.2 ± 11.6
LPS (min) 16.1 ± 6.5 16.5 ± 3.2 19.0 ± 4.2 31.0 ± 11.9
# of cycles 5.9 ± 0.2 5.8 ± 1.2 5.8 ± 0.2 5.3 ± 0.2
Cycle duration (min) 97.7 ± 3.2 95.5 ± 2.8 92.3 ± 2.8 93.0 ± 4.4
TST (min) 670.6 ± 10.2 661.5 ± 10.6 619.3 ± 11.8*** 580.4 ± 14.7***
Stage 1 (%) 5.6 ± 0.7 6.5 ± 0.8 7.0 ± 0.6* 7.8 ± 0.6***
Stage 2 (%) 40.5 ± 1.4 39.0 ± 1.6 38.2 ± 1.3 37.0 ± 1.8*
SWS (%) 21.3 ± 1.3 21.2 ± 1.5 18.4 ± 1.3** 16.2 ± 1.3***
REM (%) 28.2 ± 1.3 27.5 ± 1.1 25.0 ± 1.1* 21.7 ± 1.2***
Sleep efficiency (%) 94.4 ± 1.2 92.2 ± 1.4 86.4 ± 1.6*** 81.6 ± 2.1***
Stage changes 172.5 ± 7.0 185.5 ± 8.3 165.6 ± 8.5 152.5 ± 6.3*
NAW 17.0 ± 2.7 18.1 ± 2.6 22.5 ± 1.8 21.4 ± 1.6
WASO (min) 29.8 ± 9.0 37.7 ± 9.4 81.1 ± 10.7*** 121.0 ± 15.9***
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Table 2: PSG assessment of sleep after administration of modafinil and MK-0249 
compared to placebo for the first 8 hours of the recovery sleep episode 
PSG variables (mean ±SE) after administration of placebo (n=22), modafinil (n=23), 
MK-0249 10mg (n=24) and MK-0249 50mg (n=24). Effect of treatment was assessed 
with repeated measures ANOVA and p values are listed. * indicates a significant 
difference from placebo; * = P<0.05, ** = P<0.01 and *** = P<0.001. 
 
 
Treatment Placebo Modafinil MK0249 10mg MK0249 50mg
# of cycles 3.5 ± 0.2 3.6 ± 0.2 3.4 ± 0.2 3.2 ± 0.2
Cycle duration (min) 97.4 ± 3.3 95.7 ± 3.5 95.7 ± 5.0 94.1 ± 4.5
TST (min) 448.7 ± 7.9 446.5 ± 5.3 421.9 ± 8.1* 395.4 ± 11.8***
Stage 1 (%) 4.3 ± 0.6 4.8 ± 0.7 5.4 ± 0.5* 5.9 ± 0.5**
Stage 2 (%) 38.9 ± 1.7 38.8 ± 1.8 38.2 ± 1.6 36.8 ± 1.9
SWS (%) 29.5 ± 1.7 29.2 ± 1.8 25.3 ± 1.6** 22.8 ± 1.9***
REM (%) 23.8 ± 1.1 23.7 ± 1.1 22.6 ± 1.1 19.3 ± 1.2***
Sleep efficiency (%) 95.3 ± 1.2 93.6 ± 1.1 88.0 ± 1.7*** 83.1 ± 2.5***
Stage changes 115.3 ± 5.5 122 ± 4.9 110.8 ± 5.8 100.3 ± 4.4*
NAW 8.7 ± 1.7 9.0 ± 1.6 11.4 ± 1.3 10.6 ± 1.2
WASO (min) 14.5 ± 6.1 15.7 ± 4.5 42.1 ± 6.7** 70.6 ± 11.2***
First 8hrs of recovery sleep episode
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Definitions: 
 
ANOVA -  Analysis of variance between groups 
BMI -  Body Mass Index 
CRC Clinical Research Centre 
EEG - Electroencephalograph 
EMG -  Electromyography 
EOG -  Electrooculography 
KDT -  Karolinska Drowsiness Test 
LPS -  Latency to persistent sleep 
MSLT -  Multiple sleep latency test 
MWT - Maintenance of wakefulness test 
NAW -  Number of awakenings 
NREM -  Non-rapid eye movement 
PSG Polysomnogram 
REM -  Rapid eye movement 
SOL - Sleep onset latency 
SWS -  Slow-wave sleep 
TST -  Total sleep time 
WASO -  Wake after sleep onset 
 
 
 
